Literature DB >> 33413173

The antiphospholipid syndrome may induce non-thrombotic internal jugular vein stenosis: two cases report.

Si-Ying Song1,2,3, Gary Rajah3,4, Yu-Chuan Ding3,5, Xun-Ming Ji2,3, Ran Meng6,7,8.   

Abstract

BACKGROUND: Antiphospholipid syndrome (APS) is associated with a high incidence of thrombotic events, either arterial thrombosis or venous thrombosis. However, APS-related non-thrombotic venous stenosis is rarely reported. CASE
PRESENTATION: This study described two cases of young women with APS-related internal jugular vein stenosis (IJVS) and reviewed current literature on this issue, including clinical features, diagnosis, and treatment.
CONCLUSIONS: IJVS is a rather rare complication of APS. Two cases were reported for the first time that high titer of antiphospholipid antibodies (aPL) might mediate direct vessel wall damage and further induce venous stenosis despite long-term standardized anticoagulation to prevent thrombus formation. Therefore, dynamic monitoring of autoantibodies and concomitant use of anticoagulants and corticosteroids may be necessary to the management of APS and its complications.

Entities:  

Keywords:  Antiphospholipid syndrome; Case report; Neuroimaging; Non-thrombotic internal jugular vein stenosis

Mesh:

Year:  2021        PMID: 33413173      PMCID: PMC7789703          DOI: 10.1186/s12883-020-02035-1

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  19 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study).

Authors:  M Bazzan; A Vaccarino; S Stella; S Sciascia; B Montaruli; M T Bertero; R Carignola; D Roccatello
Journal:  Lupus       Date:  2015-12-08       Impact factor: 2.911

3.  Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome.

Authors:  Patricia Redecha; Claus-Werner Franzke; Wolfram Ruf; Nigel Mackman; Guillermina Girardi
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 4.  Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence.

Authors:  Gabriela Medina; Eduardo Briones-García; María Pilar Cruz-Domínguez; Oscar I Flórez-Durante; Luis J Jara
Journal:  Autoimmun Rev       Date:  2017-02-13       Impact factor: 9.754

Review 5.  Antiphospholipid syndrome.

Authors:  Wendy Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants.

Authors:  Katrien Devreese; Kathelijne Peerlinck; Marc F Hoylaerts
Journal:  Blood       Date:  2009-11-25       Impact factor: 22.113

7.  Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Robert Lapinski; Waander L van Heerde; Chris P Reutelingsperger; Pojen P Chen; Thomas L Ortel
Journal:  Blood       Date:  2004-07-08       Impact factor: 22.113

8.  Intracranial hypertension induced by internal jugular vein stenosis can be resolved by stenting.

Authors:  D Zhou; R Meng; X Zhang; L Guo; S Li; W Wu; J Duan; H Song; Y Ding; X Ji
Journal:  Eur J Neurol       Date:  2017-12-07       Impact factor: 6.089

Review 9.  The antiphospholipid syndrome: still an enigma.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

10.  Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.

Authors:  Monica Galli; Giovanna Borrelli; Eva Marie Jacobsen; Rosa Maria Marfisi; Guido Finazzi; Roberto Marchioli; Finn Wisloff; Stefana Marziali; Olivier Morboeuf; Tiziano Barbui
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.